• “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>QIAGEN购买德国生物信息学公司BIOBASE的资产

    重庆时时彩全天计划: QIAGEN购买德国生物信息学公司BIOBASE的资产

    互联网2014年5月26日 8:58 点击:2664

    时时彩网络平台 www.qlgr.net 凯杰 QIAGEN  


    2014年5月20日 QIAGEN公司宣布,它已经购买了德国公司BIOBASE的资产,这是一家生物学数据库的供应商。QIAGEN表示,BIOBASE将更名为QIAGEN Wolfenbüttel。同时,BIOBASE的CEO将加入QIAGEN,作为新公司的总经理。具体的交易金额未透露。

    BIOBASE公司成立于2007年,是一家生物信息学公司,能够为生命科学行业提供领先的生物学数据库、知识挖掘工具和分析软件。其数据库支持功能和基因调控分析、变异注释、药物遗传学分析等。

    BIOBASE的资源包括人类基因突变数据库(HGMD),它提供遗传病的突变信息;GenomeTrac,包含致病性变异的数据;PharmacoGenomic突变数据库(PGMD),作为定位那些影响药物反应的变异的资源;以及转录因子结合位点数据库,包括真核生物转录因子和miRNA的信息。该公司提供免费版和收费版的资源。

    QIAGEN表示,这些数据库将作为独立的解决方案继续出售,同时,它们的内容也将整合到现有的信息学方案中,包括Ingenuity知识库。Ingenuity在去年被QIAGEN收购,更名为Qiagen Redwood City。

    据介绍,BIOBASE的信息将让Ingenuity Clinical受益,这是一个基于网络的决策支持系统,适用于临床新一代测序检测。目前有20个临床实验室正在试用,包括Partners Healthcare、埃默里遗传实验室和GeneDx。同时,HGMD的数据已向Ingenuity Variant Analysis软件的客户开放。

    QIAGEN的CEO Peer Schatz表示,通过此次收购,QIAGEN将满足客户在解释NGS所产生的海量数据上的需求。此外,BIOBASE提供的内容将扩大该公司在序列数据的临床解释中的“竞争优势”。

    埃默里遗传实验室的执行主管Madhuri Hegde谈道:“测序数据的解读需要了解高质量的内容,以便快速可靠地从测序数据中获得有关变异及相关表型的最新信息。将BIOBASE的内容(如HGMD和PGMD)整合到QIAGEN不断扩展的信息学组合(包括Ingenuity Variant Analysis和Ingenuity Clinical等工具),对推出诊断检测的临床实验室而言很宝贵。”

    除了BIOBASE和Ingenuity,QIAGEN还在半年前收购了丹麦一家生物信息学公司CLC Bio。CLC Bio开发并推广软件,以分析来自新一代测序仪和传统Sanger测序仪的基因组数据。其产品组合包括CLC Genomics Workbench、CLC Main Workbench和CLC Genomics Server。

    QIAGEN integrates content from BIOBASE, including widely adopted HGMD, with its leading offering for biological data interpretation

    • New biomedical content resources strengthen QIAGEN’s industry-leading bioinformatics portfolio
    • Expansion will offer clinical researchers the most comprehensive, high-quality and up-to-date literature source for gene variant and disease phenotype associations
    • Expert-curated hereditary variants from HGMD are now available to customers using QIAGEN’s Ingenuity Variant Analysis shows commitment to use synergies for rapid integration.

    HILDEN, Germany, and GERMANTOWN, Maryland, MAY 20, 2014 — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its industry-leading portfolio of bioinformatics solutions with additional content from BIOBASE, a provider of expertly curated biological databases, software and services. With access to HGMD, an especially in clinical markets widely used biomedical data resource as well as to other unique content, QIAGEN expand its world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis – further strengthening its market-leading position in the analysis and interpretation of sequencing data. QIAGEN’s growing bioinformatics and next-generation sequencing (NGS) franchises is positioned to benefit from the integration of BIOBASE, its assets and employees and will benefit the expansion of relationships with thousands of clinical labs and NGS users in life sciences.

    “The ability of next-generation sequencing to rapidly deliver genomic insights is opening up new frontiers for clinical research and medicine, and QIAGEN is strategically addressing customers’ needs to interpret the massive amounts of data generated by NGS. With HGMD and other content from BIOBASE, a respected organization with a dedicated team and robust line of unique databases and software, QIAGEN is further extending its competitive advantage as the overall market leader for clinical interpretation of human sequencing data,” said Peer M. Schatz, Chief Executive Officer of QIAGEN. “Already today, more than 15,000 users worldwide rely on QIAGEN’s bioinformatics products for interpretation – and have processed over of over a quarter of a million genome sequences. HGMD is a unique fit with our offering and will integrate well. We expect to drive additional adoption of this leading literature-based knowledge base used by clinical reference labs for annotating hereditary variants, as well as BIOBASE’ other solutions by having integrated them into interpretation solutions shared with our Ingenuity Knowledge Base – adding value for QIAGEN and BIOBASE customers and accelerating our growth drivers in NGS and bioinformatics.”

    BIOBASE offers well-structured interpretation solutions assembled by highly qualified subject-matter experts and organized in an accessible and easily searchable manner that enables scientists and clinical labs to identify connections between disparate pieces of information and apply that knowledge. In addition to continuing to market BIOBASE products on a standalone basis, QIAGEN already began integrating first products into QIAGEN’s expanding Ingenuity Knowledge Base and the QIAGEN bioinformatics solutions that draw upon it, including:

    • HGMD® Human Gene Mutation Database – providing comprehensive data on human inherited disease mutations. Widely used in human genetics research, diagnostics and personal genomics, HGMD enables quick access to single mutation queries and advanced search applications.
    • PGMD™ PharmacoGenomic Mutation Database – identifying all published gene variants that have been shown to affect drug response in patients, with multiple delivery models for accessing this data, including an intuitive exploratory interface and a data download for in-house analysis systems.

    “Interpretation of sequencing data requires access to high-quality, expert-curated content to be able to quickly and reliably assess the most up-to-date information about variants and associated phenotypes from sequencing data”, said Madhuri Hegde, Executive Director, Emory Genetics Laboratory. “Integrating BIOBASE content offerings such as HGMD and PGMD into QIAGEN’s growing informatics portfolio and leveraging it with industry leading tools like Ingenuity Variant Analysis and Ingenuity Clinical will be invaluable to clinical labs launching sequence-based diagnostic tests.”

    HGMD integration is now available to customers of QIAGEN’s Ingenuity Variant Analysis. Rapid further integration of BIOBASE solutions with QIAGEN’s Ingenuity Knowledge Base will help create a springboard for Ingenuity® Clinical, QIAGEN’s forthcoming clinical NGS decision-support solution. Ingenuity Clinical is a new web-based solution to deliver faster, easier-to-use and high-confidence clinical interpretation and reporting of insights from NGS-based tests. More than 20 clinical testing laboratories are taking part in an early access program for Ingenuity Clinical, which is specifically designed to address challenges of scale, speed and decision support for healthcare laboratories adopting NGS.

    About QIAGEN
    QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of March 31, 2014, QIAGEN employed approximately 4,000 people in over 35 locations worldwide. Further information can be found at //www.qiagen.com.

    (来源: 互联网 )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 腾讯彩票中奖 广东好彩1开奖结果167期 竞彩店微信 从9张扑克牌中选出4 15876计划网时时彩 河北20选五基本走势图 双色球走势中彩村 彩票计划软件吉林快三 快乐12选5走势图四川 澳客北单比分直播 吉林十一选五中奖号码的真实规律 幸运农场走势 pk10杀号 牛牛流星打泡泡 平码六肖全中多少倍